Kalvista Pharmaceuticals Inc - Asset Resilience Ratio
Kalvista Pharmaceuticals Inc (KALV) has an Asset Resilience Ratio of 19.32% as of October 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Kalvista Pharmaceuticals Inc (KALV) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Kalvista Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See what is Kalvista Pharmaceuticals Inc's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Kalvista Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Kalvista Pharmaceuticals Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $65.66 Million | 19.32% |
| Total Liquid Assets | $65.66 Million | 19.32% |
Asset Resilience Insights
- Good Liquidity Position: Kalvista Pharmaceuticals Inc maintains a healthy 19.32% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Kalvista Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Kalvista Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Kalvista Pharmaceuticals Inc (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Kalvista Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-04-30 | 35.49% | $89.00 Million | $250.77 Million | -40.38pp |
| 2024-04-30 | 75.87% | $178.61 Million | $235.40 Million | +25.04pp |
| 2023-04-30 | 50.84% | $93.14 Million | $183.20 Million | -15.61pp |
| 2022-04-30 | 66.45% | $135.47 Million | $203.88 Million | -6.47pp |
| 2021-04-30 | 72.91% | $198.34 Million | $272.01 Million | +16.80pp |
| 2020-04-30 | 56.12% | $51.92 Million | $92.53 Million | -2.13pp |
| 2019-04-30 | 58.24% | $68.81 Million | $118.13 Million | -- |
| 2018-04-30 | 0.00% | $0.00 | $61.39 Million | -- |
| 2017-04-30 | 0.00% | $0.00 | $34.34 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $56.79 Million | -- |
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which … Read more